ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical
stage specialty biopharmaceutical company developing first-in-class
drugs for treatment of inflammatory and renal diseases, announces
publication of an article in the peer-reviewed Journal of the
American Heart Association addressing the role of NLRP3
inflammasomes in PAD. ZyVersa’s Inflammasome ASC Inhibitor IC 100
inhibits the inflammasome adaptor protein ASC, a component of
multiple types of inflammasomes including NLRP3 inflammasomes.
In the paper titled, “NLRP3 Inflammasome Activation in
Peripheral Arterial Disease,” the authors evaluated human
peripheral arteries from patients undergoing limb amputation and
serum collected prior to surgery. Data demonstrated an association
between NLRP3, macrophage accumulation, and calcification in
arteries of patients with PAD, suggesting that NLRP3 inflammasome
activation may be a driver of the disease. Following are key
findings reported in the paper:
- NLRP3 protein was significantly
increased in vessels from patients with PAD compared with control
vessels, and it was present in macrophages in the vicinity of
calcification, along with IL-1β and caspase-1
- Likewise, serum NRLP3 protein levels
and IL-1β were significantly increased in PAD patients compared to
controls, suggesting activation of NLRP3 Inflammasomes both locally
and systemically
The authors stated, “Given that PAD is associated with increased
risk of cardiac comorbidity and cardiac and cerebrovascular
ischemic events, further studies are now needed to determine the
clinical implication of pharmacologically reducing vascular
inflammation in this cohort before surgical intervention.
Inhibition of the NLRP3 inflammasome activation or downstream
signaling cascade may be beneficial to the reduction of
inflammatory-driven PAD.” To read the article, Click
Here.
“The research published in the Journal of the American Heart
Association demonstrating that NLRP3 inflammasome activation is
associated with calcification in arteries of patients with PAD,
along with research referenced by the authors on the potential role
of NLRP1 activation in PAD, provides support for inhibiting
multiple types of inflammasomes by targeting inflammasome ASC, the
mechanism of action of IC 100.” commented Stephen C. Glover,
ZyVersa’s Co-founder, Chairman, CEO and President. To review a
white paper summarizing the mechanism of action and preclinical
data for IC 100, Click Here.
About Inflammasome ASC Inhibitor IC 100
IC 100 is a novel humanized IgG4 monoclonal antibody that
inhibits the inflammasome adaptor protein ASC. IC 100 was designed
to attenuate both initiation and perpetuation of the inflammatory
response. It does so by binding to a specific region of the ASC
component of multiple types of inflammasomes, including NLRP1,
NLRP2, NLRP3, NLRC4, AIM2, Pyrin. Intracellularly, IC 100 binds to
ASC monomers, inhibiting inflammasome formation, thereby blocking
activation of IL-1β early in the inflammatory cascade. IC 100 also
binds to ASC in ASC Specks, both intracellularly and
extracellularly, further blocking activation of IL-1β and the
perpetuation of the inflammatory response that is pathogenic in
inflammatory diseases. Because active cytokines amplify adaptive
immunity through various mechanisms, IC 100, by attenuating
cytokine activation, also attenuates the adaptive immune
response.
About ZyVersa Therapeutics, Inc.
ZyVersa (Nasdaq: ZVSA) is a clinical stage specialty
biopharmaceutical company leveraging advanced, proprietary
technologies to develop first-in-class drugs for patients with
renal and inflammatory diseases who have significant unmet medical
needs. The Company is currently advancing a therapeutic development
pipeline with multiple programs built around its two proprietary
technologies – Cholesterol Efflux Mediator™ VAR 200 for treatment
of kidney diseases, and Inflammasome ASC Inhibitor IC 100,
targeting damaging inflammation associated with numerous CNS and
other inflammatory diseases. For more information, please visit
www.zyversa.com.
Cautionary Statement Regarding Forward-Looking
Statements
Certain statements contained in this press release regarding
matters that are not historical facts, are forward-looking
statements within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended, and the Private Securities
Litigation Reform Act of 1995. These include statements regarding
management’s intentions, plans, beliefs, expectations, or forecasts
for the future, and, therefore, you are cautioned not to place
undue reliance on them. No forward-looking statement can be
guaranteed, and actual results may differ materially from those
projected. ZyVersa Therapeutics, Inc (“ZyVersa”) uses words such as
“anticipates,” “believes,” “plans,” “expects,” “projects,”
“future,” “intends,” “may,” “will,” “should,” “could,” “estimates,”
“predicts,” “potential,” “continue,” “guidance,” and similar
expressions to identify these forward-looking statements that are
intended to be covered by the safe-harbor provisions. Such
forward-looking statements are based on ZyVersa’s expectations and
involve risks and uncertainties; consequently, actual results may
differ materially from those expressed or implied in the statements
due to a number of factors, including ZyVersa’s plans to develop
and commercialize its product candidates, the timing of initiation
of ZyVersa’s planned preclinical and clinical trials; the timing of
the availability of data from ZyVersa’s preclinical and clinical
trials; the timing of any planned investigational new drug
application or new drug application; ZyVersa’s plans to research,
develop, and commercialize its current and future product
candidates; the clinical utility, potential benefits and market
acceptance of ZyVersa’s product candidates; ZyVersa’s
commercialization, marketing and manufacturing capabilities and
strategy; ZyVersa’s ability to protect its intellectual property
position; and ZyVersa’s estimates regarding future revenue,
expenses, capital requirements and need for additional
financing.
New factors emerge from time-to-time, and it is not possible for
ZyVersa to predict all such factors, nor can ZyVersa assess the
impact of each such factor on the business or the extent to which
any factor, or combination of factors, may cause actual results to
differ materially from those contained in any forward-looking
statements. Forward-looking statements included in this press
release are based on information available to ZyVersa as of the
date of this press release. ZyVersa disclaims any obligation to
update such forward-looking statements to reflect events or
circumstances after the date of this press release, except as
required by applicable law.
This press release does not constitute an offer to sell, or the
solicitation of an offer to buy, any securities.
Corporate and IR Contact:Karen CashmereChief
Commercial
Officerkcashmere@zyversa.com786-251-9641
Media ContactsTiberend Strategic Advisors,
Inc.Casey McDonaldcmcdonald@tiberend.com646-577-8520
Dave Schemeliadschemelia@tiberend.com609-468-9325
ZyVersa Therapeutics (NASDAQ:ZVSA)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
ZyVersa Therapeutics (NASDAQ:ZVSA)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024